u/nhs_waitlist_n

Appetite returning before the scale moves follows from the mechanism: the appetite effect is the proximal one and weight is the lagging integrated outcome.

Went looking for the registered protocol to see whether the endpoint had changed. It had not, which was reassuring and worth checking.

Not convinced. Interval stretching changes your exposure profile, not just the total, and the two are not equivalent.

Correction: that trial is the diabetes programme and the figure you quoted is its glycaemic endpoint, not a weight result.

On means, which this board treats as targets and which are nothing of the sort.

A reported mean body weight change is the centre of a distribution that in these trials is very wide. Substantial numbers of participants did much better, and substantial numbers did considerably worse while remaining on the drug and in the analysis.

Quoting the mean as an expectation therefore misleads in both directions: it makes ordinary results look like failures and it makes exceptional results look normal. If a paper publishes the distribution — and several do, in the appendix — look at that instead. It is far more informative than the number in the abstract.

Referral link removed and the post left up. No links of any kind here, and that rule is not negotiable.

Added a nation tag — the answers to this question differ across the four.

Added a nation tag — the answers to this question differ across the four.

network and address, checked twice, before anything else

a press release is not a publication

Left up. It names a nation and an ICB, which is all we ask of a pathway post.

Small fix — that is the Scottish pathway. The post is asking about England and the answer is different.

GIP receptor biology is genuinely unsettled — there is a live argument about agonism versus antagonism at the receptor — and the clinical results are robust regardless, which is an uncomfortable and interesting position.

What is and is not the supplier’s fault, since this board generates unfair complaints.

Not theirs: the network fee, chain congestion, confirmation time, the rate moving between quote and send, and a payment sent on the wrong chain. Theirs: which networks they accept, how quickly they credit a confirmed payment, and whether the address they gave you was correct and communicated clearly.

Keeping those columns separate makes the reports here far more useful. A thread titled "supplier took my payment" that turns out to describe forty minutes of unconfirmed transaction helps nobody and follows people around for years.

Why mechanism talk keeps misleading people, including me.

A mechanism tells you a direction. It does not tell you a magnitude, a timescale, or whether the pathway is operative at the exposures involved. "Receptor X is expressed in tissue Y" is a fact; "therefore effect Z in a person" is a hypothesis with several missing steps.

The corrective is boring and it works: ask whether the evidence is preclinical or human, ask what exposure was used, and read the limitations section before the abstract. Most of the confidently wrong posts on this board — several of them mine — skipped all three.

A1c is a three-month average and it lags everything

My triglycerides moved and it turned out to have nothing to do with glucose at all.

Variability dropped before the average did, which was visible on the sensor and invisible on the lab result.

a few kilos of drift is not a relapse

Right — appetite returns before the scale moves, which is the early signal people miss.

GP said no in the spring, specialist said yes eighteen months later. Same person, same numbers.

dose response is not linear and nobody should assume it is

Referral link removed and the post left up. No links of any kind here, and that rule is not negotiable.

Tried to build a mental model from mechanism alone and produced a confident prediction that the trial data flatly contradicted.

England, Scotland, Wales and Northern Ireland are four different pathways

specialist service, not GP, for tier 3 in most of England

The habits from the losing phase are what carry it now. That is not inspirational, it is just what happened.

Why the monthly pricing tracker works, and the rule that makes it work.

Members post the pharmacy, the product, the month and the price they actually paid — not an advertised offer, not a first-month discount. No links of any kind are permitted, which removes the entire incentive to post anything other than what happened.

The result is that the spread between pharmacies in a given month is visible, and it is consistently larger than people expect. That single table has saved members here more money than every other thread on the board combined, and it survives only because the no-links rule is enforced without exception.

discontinuation rate is a result, not a footnote

maintenance is where the logistics finally get boring, which is the point

Spent an evening on the receptor distribution literature and the side-effect map suddenly stopped looking random.